financetom
Business
financetom
/
Business
/
Update: Vail Resorts Fiscal Q3 Earnings, Sales Lag Estimates, Cuts Full-Year Net Income Guidance; Shares Slump Premarket
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Vail Resorts Fiscal Q3 Earnings, Sales Lag Estimates, Cuts Full-Year Net Income Guidance; Shares Slump Premarket
Jun 7, 2024 2:54 AM

05:30 AM EDT, 06/07/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.)

Vail Resorts ( MTN ) shares traded more than 6% lower in premarket activity Friday after the company reported overnight a lower than expected earnings and sales for fiscal Q3 while lowering its full-year net income guidance.

The company reported fiscal Q3 earnings Thursday of $9.54 per diluted share, up from $8.18 a year earlier.

Analysts polled by Capital IQ expected $10.03.

Revenue in the quarter ended April 30 rose to $1.28 billion from $1.24 billion a year ago.

Analysts surveyed by Capital IQ expected $1.30 billion.

The company expects net income in fiscal 2024 of $224 million and $256 million, down from previous guidance of $270 million to $325 million. Analysts polled by Capital IQ expect $291.7 million.

Vail Resorts ( MTN ) maintained its quarterly dividend at $2.22 a share, payable July 10 to shareholders of record on June 25.

Price: 182.00, Change: -11.95, Percent Change: -6.16

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall
Oncternal Therapeutics Ends Clinical Studies, Explores Strategic Options; Shares Fall
Sep 13, 2024
11:13 AM EDT, 09/12/2024 (MT Newswires) -- Oncternal Therapeutics' ( ONCT ) shares sank 58% in recent Thursday trading after the company said it has decided to discontinue its clinical studies and explore strategic alternatives. The company also said it will discontinue all product development activities, lay off some staff, and implement other cost-cutting measures while exploring alternatives, which may...
--Street Color: US FDA Authorizes Over-the-Counter Hearing Aid Software for Apple's AirPods Pro
--Street Color: US FDA Authorizes Over-the-Counter Hearing Aid Software for Apple's AirPods Pro
Sep 13, 2024
11:09 AM EDT, 09/12/2024 (MT Newswires) -- Price: 222.76, Change: +0.10, Percent Change: +0.04 ...
Update: Moderna Shares Fall After Cutting Annual R&D Spending by $1.1 Billion From 2027
Update: Moderna Shares Fall After Cutting Annual R&D Spending by $1.1 Billion From 2027
Sep 13, 2024
11:09 AM EDT, 09/12/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and the first paragraph.) Moderna ( MRNA ) shares fell more than 18% in recent Thursday trading after the company said it is reducing its annual R&D expense by about $1.1 billion starting in 2027 in light of recent commercial challenges. The company now...
Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing
Buckle Insider Sold Shares Worth $854,496, According to a Recent SEC Filing
Sep 13, 2024
11:08 AM EDT, 09/12/2024 (MT Newswires) -- Dennis H Nelson, Director, President & CEO, on September 10, 2024, sold 20,453 shares in Buckle (BKE) for $854,496. Following the Form 4 filing with the SEC, Nelson has control over a total of 2,310,552 shares of the company, with 324,000 shares held directly and 1,986,552 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/885245/000088524524000087/xslF345X05/wk-form4_1726153070.xml Price: 41.56,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved